Navigation Links
Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
Date:7/8/2008

Corifollitropin alfa meets primary endpoints in ENGAGE Trial

KENILWORTH, N.J., July 8 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE: SGP) announced today that corifollitropin alfa, its experimental, sustained follicle stimulant (SFS) met its primary endpoints in the Phase III ENGAGE trial, according to data presented during a Schering-Plough-sponsored symposium at the 24th annual meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Barcelona, Spain.

The ongoing pregnancy rate, the primary endpoint of this non-inferiority trial, obtained in the 150 mcg corifollitropin alfa treatment arm (38.9 percent per started cycle) was similar to that achieved in patients receiving 200 IU recombinant FSH (follitropin beta) (38.1 percent per started cycle). The number of oocytes retrieved (co-primary endpoint) was within the limits of clinical equivalence, and the estimated difference of +1.2 was in favor of the corifollitropin alfa 150 mcg treatment arm.

Further results will be submitted for presentation at a future medical meeting.

Study Design

ENGAGE is the largest double-blind fertility trial ever performed. ENGAGE was a non-inferiority trial designed to compare corifollitropin alfa 150 mcg to 200 IU follitropin beta. A total of 1,509 patients (>60 kg) at 34 IVF clinics in North America and Europe were randomized to receive either corifollitropin alfa 150 mcg or a daily dose of 200 IU recombinant FSH, followed by recombinant FSH (maximum 200 IU/day) from stimulation day 8 onward. Starting on stimulation day 5, all patients were scheduled to receive 0.25mg gonadotropin-releasing hormone (GnRH) antagonist until triggering of final oocyte maturation by a urinary human chorionic g
'/>"/>

SOURCE Schering-Plough Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
2. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
3. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
5. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
6. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
7. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
8. Schering-Plough Reports Top-Line Results of the IDEAL Study
9. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
10. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
11. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... -- "Whether it,s our family, our friends, all of ... a single sentence, Dr. Anthony Coyle , senior ... Centers for Therapeutic Innovation (CTI), sums up what ... biopharmaceutical companies. CTI,s unique model allows ... and the National Institutes of Health (NIH) to bridge ...
(Date:3/26/2015)... , March 26, 2015 Over-the-counter ... average American consumer. However, a new survey of ... ailments from the common cold to diabetes, can ... The research, conducted by the Private Label Manufacturers ... over-the-counter healthcare products, including those essential for treatment ...
(Date:3/26/2015)... Research and Markets ( ... "Global Smart Wearable Healthcare Devices and Services ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The analysts forecast ... market to grow at a CAGR of 30.42% ... covers the present scenario and the growth prospects ...
Breaking Medicine Technology:Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Consumers can keep over-the-counter medicine affordable by using store brands 2Global Smart Wearable Healthcare Devices and Services Market 2015-2019 WITH Apple, At&T, Ee, Google, Samsung, Sprint, Telefonica & T-Mobile Dominating 2
(Date:3/26/2015)... (PRWEB) March 26, 2015 Dr. ... 32nd annual Dallas Rhinoplasty Symposium and has trained ... reiterated the importance of evidence based medicine (EBM), that ... from well conducted research. , "We often hear from ... rhinoplasty, and while we are certainly not trying to ...
(Date:3/26/2015)... March 26, 2015 Florida Hospital teamed up ... For Your Health campaign and live Dr. Oz event, which ... March 21st. More than a thousand people came out to ... living. , The world renowned cardiothoracic surgeon and Emmy ... Linda Hurtado and a panel of experts for the live ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Behavioral ... consulting firm, announced the release of BathroomMap® , ... to increase access to public restrooms for travelers, especially ... bathroom apps, BathroomMap does not facilitate a paid, social ... to identify and rate local establishments that have clean, ...
(Date:3/26/2015)... San Frencisco, CA (PRWEB) March 26, 2015 ... Implant Center are proud to announce expanded offerings for ... The San Francisco Dental Implant Center has long been ... efforts have expanded its offerings to meet the strong ... pride in our reputation as a top-rated dental implant ...
(Date:3/26/2015)... Mirada, CA (PRWEB) March 26, 2015 ... shooting guard Wesley Matthews is out for the season ... This injury occurred while the Trail Blazers were competing ... sports medicine specialist, Izzy Silva, M.D., who ... on Matthews' injury and whether it could be prevented. ...
Breaking Medicine News(10 mins):Health News:Dr. Rod Rohrich Explores Evidence Based Innovations and Safety at the 32nd Annual Dallas Rhinoplasty Symposium 2Health News:Florida Hospital Welcome Dr. Oz to Tampa and Invites the Community to Attend Educational Seminars Hosted by Florida Hospital Physicians 2Health News:Florida Hospital Welcome Dr. Oz to Tampa and Invites the Community to Attend Educational Seminars Hosted by Florida Hospital Physicians 3Health News:New Bathroom Finder App, BathroomMap®, Helps People with Medical Needs Who Urgently Need a Bathroom When Traveling 2Health News:New Bathroom Finder App, BathroomMap®, Helps People with Medical Needs Who Urgently Need a Bathroom When Traveling 3Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 2Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 4
... a Saint Louis University researcher, investigators found that a new ... hepatitis C patients who have not responded to previous treatment. ... , offer a new option for hepatitis C patients, and ... make their condition difficult to treat. "This ...
... Receptor Mutation Test May Be Key To Identifying Patient ... Calif., June 16 Clarient, Inc. (Nasdaq: ... services resource for pathologists, oncologists, and the pharmaceutical industry, ... test that can help physicians select the proper therapy ...
... CAMBRIDGE, England and SAN FRANCISCO, California, June ... leader in infrastructure software for the enterprise, today announced,that ... its,information processing solutions to securely capture, route, store and ... clinicians will be,able to view all of their patients, ...
... ... Singapore Economic Development Board (EDB) set up endowment fund. , ... Singapore (PRWEB) June 16, 2009 -- Singapore,s ... plant. The new plant is GlaxoSmithKline,s (GSK) first primary vaccine manufacturing facility and its ...
... ... hypertension medications and the financial help available for those living with the disease. ... (Vocus) June 16, 2009 -- ... those with pulmonary hypertension . The page is a pulmonary hypertension-specific source of help ...
... of ISI Web of Knowledge To Advance Research4Life Partnership ... The Healthcare & Science business of Thomson Reuters today ... developing world with access to critical scientific research. Special ... include Current Contents Connect, Medline, EndNote Web, and ResearcherID, ...
Cached Medicine News:Health News:Good news for some hard-to-treat hepatitis C patients 2Health News:Clarient Launches New Gene Mutation Test to Help Select Therapy for Non-Small Cell Lung Cancer 2Health News:Clarient Launches New Gene Mutation Test to Help Select Therapy for Non-Small Cell Lung Cancer 3Health News:Clarient Launches New Gene Mutation Test to Help Select Therapy for Non-Small Cell Lung Cancer 4Health News:Greater Cincinnati Behavioral Health Services Standardizes on Autonomy's Meaning-Based Technologies 2Health News:Greater Cincinnati Behavioral Health Services Standardizes on Autonomy's Meaning-Based Technologies 3Health News:GlaxoSmithKline Opens $600million Vaccine Plant In Singapore 2Health News:GlaxoSmithKline Opens $600million Vaccine Plant In Singapore 3Health News:New Source of Information on Pulmonary Hypertension Medications 2Health News:Thomson Reuters Partners with Research4Life to Bring Scientific Research Information Resources to Developing Countries Around the World 2Health News:Thomson Reuters Partners with Research4Life to Bring Scientific Research Information Resources to Developing Countries Around the World 3
The Budde Halo Retractor Side Rail Support is designed for the adaptation and attachment of the Budde Halo Brain Retractor System to the operating room table when a conventional skull clamp is not us...
Cone Ring Curettes, length 9" (229 mm), ring diameter (I.D.) 5/16" (8 mm)....
Scoville Ruptured Disc Curettes, length 10" (254 mm), cup size 4 x 10 mm....
PG Magnum Cup Curettes with large capacity cup sizes, total length 12.6" (32 cm) handle length 7.8" (20 cm), handle diameter 1.12" (3 cm), working distance 4.7" (12 cm)....
Medicine Products: